Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27542435 | 0.85 | ALDH1A1 (0.39) | MAPK1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL838659 | 0.81 | TP53 (0.57) | MEN1KMT2ALMNAHTTTP53 | |
| SCHEMBL27817028 | 0.79 | CA1 (0.36) | MAPK1MEN1KMT2ALMNAHTT | |
| SCHEMBL13331746 | 0.79 | CA1 (0.36) | MAPK1MEN1KMT2ALMNAHTT | |
| SCHEMBL2413818 | 0.78 | MAPK1 (0.42) | MAPK1TSHRMEN1KMT2ALMNA | |
| SCHEMBL27747529 | 0.78 | APLNR (0.48) | LMNAALDH1A1ERN1APLNRPDE2A | |
| SCHEMBL27490666 | 0.76 | MAPK1 (0.41) | MAPK1TSHRMEN1KMT2ALMNA | |
| SCHEMBL13331730 | 0.75 | LPAR1 (0.41) | TSHRLMNAHTTERN1APLNR | |
| SCHEMBL28034745 | 0.75 | HTR2A (0.44) | HTTALDH1A1ERN1 | |
| SCHEMBL10277959 | 0.75 | ERN1 (0.31) | TSHRMEN1KMT2AHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411365-B1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-03-19 | — | — | EP | disclosed |
| US-20130172335-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8450313-B2 | 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-05-28 | — | — | US | disclosed |
| CN-101808992-B | 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives | HOFFMANN LA ROCHE | 2012-09-26 | — | — | CN | disclosed |
| US-8268820-B2 | 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120232071-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HUNZIKER DANIEL (CH) | 2012-09-13 | — | — | US | disclosed |
| EP-2411365-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| CN-1993323-B | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE | 2011-04-20 | — | — | CN | disclosed |
| CN-101896469-A | Substituted hydantoins as MEK kinase inhibitors | HOFFMANN LA ROCHE | 2010-11-24 | — | — | CN | disclosed |
| CN-101098870-B | Novel fused imidazole derivative | BANYU PHARMA CO LTD | 2010-11-03 | — | — | CN | disclosed |
| WO-2010108903-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249124-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| CN-101808992-A | 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives | HOFFMANN LA ROCHE | 2010-08-18 | — | — | CN | disclosed |
| CN-101098870-A | Novel fused imidazole derivative | BANYU PHARMA CO LTD (JP) | 2008-01-02 | — | — | CN | disclosed |
| CN-1993323-A | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172335-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | MAPK1 1352/4885TSHR 138/4885MEN1 2227/4885 |
| US-20100249124-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | MAPK1 1231/4885TSHR 136/4885MEN1 2174/4885 |
| US-20120232071-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | MAPK1 1352/4885TSHR 138/4885MEN1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.